Ziqi Huang
Key Laboratory Of Cancer Immunology And Biotherapy, State Key Laboratory Of Druggability Evaluation And Systematic Translational Medicine
Tianjin, 300060, China
Tianjin, 300060, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
USP18-stabilized ELF3 drives glycolysis and malignant progression in lung adenocarcinoma.
Journal: Acta biochimica et biophysica Sinica
Published: May 29, 2026
scRNA-seq reveals that VEGF signaling mediates the response to neoadjuvant anlotinib combined with PD-1 blockade therapy in non-small cell lung cancer.
Journal: Journal of translational medicine
Published: January 11, 2025
Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma.
Journal: Cancer gene therapy
Published: September 17, 2023
Non-spatial and spatial heterogeneity revealed a suppressive immune feature of Siglec-15 in lung adenocarcinomas.
Journal: Journal of translational medicine
Published: July 02, 2023
Somatic copy number alterations are predictive of progression-free survival in patients with lung adenocarcinoma undergoing radiotherapy.
Journal: Cancer biology & medicine
Published: August 27, 2021
Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy.
Journal: Cancer gene therapy
Published: July 08, 2021
Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Journal: Frontiers in immunology
Published: June 10, 2021
Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma.
Journal: Neoplasia (New York, N.Y.)
Published: February 04, 2021
Showing 1-10 of 10
Last Updated: 09/26/2026